Banks still not so safe

Published 03-MAY-2019 13:41 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

With reporting season underway, we can see how the aftermath of the royal commission is still working its way through the financial services sector.

In its half year results, NAB reported revenue growth at just 1.4% while expenses were up 1.7%. Its earnings included $525 million in customer-related remediation costs, which resulted in the interim dividend being cut by 16% from 99 cents down to 83 cents per share.

ANZ reported a 2% increase in cash profit and held its interim dividend at $0.80 cents per share. Westpac is due to report on Monday but has already advised the market of an additional $260 million in remediation costs, adding to a total profit downgrade of more than $750 million.

Based on this you would think we should continue to stay clear of the banks, but as Mr Buffett says ‘buy in doom and sell in boom’. While the banks have been falling since early 2015, they have been trading up this calendar year with ANZ performing the best up over 11%, followed by Westpac up nearly 10%, NAB up around 7% and CBA 3.5%.

So am I bullish on the banks? I am getting really close, as I think these stocks will do well in the second half of this year and over the coming years.

This week AMP also reported a $1.8 billion net outflow in its cash flow update for the first quarter. While its shares are down over 8% this year, I believe it is starting to turn, so we may see a different story in the second half of the year.

With the RBA set to meet next week it’s highly likely we could see an interest rate cut. Prior to our last federal election, the RBA cut rates on the basis of global growth figures and lower inflation levels. Interestingly, this is quite similar to the situation we currently face with inflation at lower than expected levels and strong performance in the global markets. That said, with a fragile housing market and fair bit of political uncertainty, I believe it would be wise for the RBA to hold interest rates right now but only time will tell.

Leading the way in the top 200 stocks is Afterpay Touch up 13%, Bravura up nearly 9% and Nine Holdings up over 8%. This week the worst performers have been Pendal Group down nearly 12%, Domain Holdings down 10% and Super Retail down nearly 9%.


So what do we expect in the market?
The Australian market has traded down this week and I expect to see this continue for another one to two weeks before it returns to being bullish over the medium to longer term. Right now, my expectation is for the market to rise over the next one or two months before falling into a low sometime in July.

I also expect the All Ordinaries Index will finally break through its previous all-time high this year that occurred on 1 November 2007 at 6,873 points.

Dale Gillham is Chief Analyst at Wealth Within and international bestselling author of How to Beat the Managed Funds by 20%. He is also author of Accelerate Your Wealth—It’s Your Money, Your Choice, which is available in book stores and online at www.wealthwithin.com.au



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X